Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 17/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6463914 | 0.92 | KDM4E (0.59) | MCHR1KDM4ELMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL6463934 | 0.92 | KDM4E (0.59) | MCHR1KDM4ELMNASMN1; SMN2ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL6455648 | 0.87 | KDM4E (0.52) | MCHR1KDM4ELMNASMN1; SMN2ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL6457352 | 0.85 | KDM4E (0.51) | MCHR1KDM4ELMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL6866791 | 0.79 | MCHR1 (0.58) | MCHR1KDM4ELMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL6866792 | 0.79 | MCHR1 (0.58) | MCHR1KDM4ELMNASMN1; SMN2ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL4263492 | 0.79 | CNR1 (0.44) | MCHR1KDM4ELMNAALDH1A1TSHR | |
| Trifluoroacetic Acid SCHEMBL6457766 | 0.78 | NPC1 (0.52) | MCHR1KDM4ELMNASMN1; SMN2MEN1 | |
| Trifluoroacetic Acid SCHEMBL6463642 | 0.78 | MCHR1 (0.64) | MCHR1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL6463260 | 0.78 | KDM4E (0.61) | MCHR1KDM4ELMNASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
| EP-1464335-A2 | Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist | Taisho Pharmaceutical Co. Ltd. (JP) | 2004-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | MCHR1 2/4885KDM4E 1190/4885LMNA 3391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.